| Abstrakt: |
A recent study conducted in Milan, Italy, explored the effectiveness of switching from intravenous to subcutaneous infliximab (IFX) in maintaining remission in patients with inflammatory bowel disease (IBD). The study found that the switch was safe and effective in maintaining clinical, biochemical, and transmural remission. The researchers used fecal calprotectin, C-reactive protein, infliximab trough levels, and anti-drug antibodies as measures of remission, and performed intestinal ultrasound and colonoscopy for disease assessment. The study concluded that ultrasound was a useful and non-invasive tool for monitoring disease progression in these patients. [Extracted from the article] |
